Tianjin Medical University General Hospital
Clinical trials sponsored by Tianjin Medical University General Hospital, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Dual-Purpose pill: roxadustat may fight both anemia and muscle wasting in dialysis Results expected Sep 2026 (estimated)
- Zipper therapy breakthrough: new combo may boost recovery in rare brain disease Results expected Dec 2026 (estimated)
- Can a JAK inhibitor tame the immune attack in NMOSD? Results expected Mar 2027 (estimated)
- New pain drug may stop chronic pain after lung surgery Results expected Mar 2027 (estimated)
- Could a surgical anesthetic calm unbearable Liver-Related itching? Results expected Apr 2027 (estimated)
-
Can a JAK inhibitor tame the immune attack in NMOSD?
Disease control OngoingThis early-phase trial tests whether baricitinib, an oral drug that blocks certain immune signals, can reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare autoimmune condition where the immune system attacks the optic nerves and spinal c…
Phase 1 • Sponsor: Tianjin Medical University General Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Promising drug may halt devastating NMOSD attacks faster
Disease control OngoingThis study tests whether eculizumab can help people having a sudden attack of NMOSD, a rare autoimmune disease that damages the nerves in the eyes and spine. The drug works by blocking part of the immune system to stop nerve injury. About 110 adults who test positive for a specif…
Phase 2 • Sponsor: Tianjin Medical University General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for MOGAD patients: drug aims to stop relapses
Disease control OngoingThis study tests whether the drug tocilizumab can safely prevent or delay relapses in people with MOGAD, a rare autoimmune disease that attacks the nervous system. About 102 participants aged 12 and older who have had at least one relapse in the past year will receive either toci…
Phase 2/3 • Sponsor: Tianjin Medical University General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Promising NMOSD attack treatment trial pulled before it began
Disease control CancelledThis study aimed to test the drug eculizumab for people having an acute attack of neuromyelitis optica spectrum disorder (NMOSD), a condition where the immune system attacks the central nervous system. The trial planned to give four weekly doses of eculizumab alongside standard s…
Phase 2 • Sponsor: Tianjin Medical University General Hospital • Aim: Disease control
Last updated Jun 26, 2026 16:48 UTC